News und Analysen
EQS-News: Abivax Announces Results of its June 6, 2025 Annual General Meeting
Annual General Shareholders’ Meeting 2025: Sonova shareholders approve all Board of Directors motions
Owens & Minor and Rotech Healthcare Mutually Agree to Terminate Previously Announced Acquisition
Owens & Minor, Inc. (NYSE: OMI) today announced it has mutually agreed with Rotech Healthcare Holdings Inc. to terminate the previously announced acquisition. Under the terms of the merger
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE)
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of real-world evidence for more than
Simulations Plus Releases ADMET Predictor® 13
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical
EQS-News: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
EQS-News: Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany
EQS-News: M1 Kliniken AG: Strong Q1 2025 with 29% EBIT Growth and Earnings per Share of EUR 0.31
EQS-News: Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it has initiated the process with the U.S. Centers for Medicare and Medicaid Services (CMS) to seek
EQS-News: MEDICLIN AG: Annual General Meeting approves all proposed resolutions
Evolva Holding SA Takes Note of GZO Shareholder Communities’ Announcementv
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the
EQS-News: Abivax Presents First Quarter 2025 Financial Results
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product
Charles River Laboratories to Present at William Blair and Jefferies Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 10:00 a.m. CT
EQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with